REAL LIFE OF MOMELOTINIB IN PATIENS WITH MYELOFIBROSIS: PRELIMINARY RESULTS OF MULTICENTER RETROSPECTIVE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE-REP (SIE 2026) - Oct 6, 2026 - Abstract #DP210; Pres time: Sep 22, 2026; 06:30 PM - 07:30 PM; Location: AREA POSTER; "The median time from MF diagnosis to MOME was 24 months(1-302).106 pa- tients (77%) had prior exposure to JAKi (ruxolitinib 98%, fe- dratinib 25%).Sixty patients (43%) received concomitant ery- thropoietin. Conclusions. Although with the limitations of its retrospec- tive nature and a short follow-up, our results confirm that MOME is effective and well-tolerated in real-world practice, in both JAKi exposed/naive patients."
Retrospective data • Hematological Disorders • Infectious Disease • Myelofibrosis
|
|
C. P. Schifone5; E. Rinaldi5; V. De Fazio6; P. Ditonno6; E. F. Laddaga6; T. M. Santeramo7; V. Carluccio7; G. Spinosa8; M. P. Sinisi8; F. A. Ciardo De Marti1; G. Tarantini7; L. Melillo8; D. Pastore5; N. Di Renzo4; P. Musto3,9; V. Pavone1; A. M. Carella2; A. Mele1
|